Loading...
•
Mar 31, 2024
Celcuity Q1 2024 Earnings Report
Celcuity reported first quarter financial results and provided a corporate update.
Key Takeaways
Celcuity reported a net loss of $21.6 million, or $0.64 loss per share, for the first quarter of 2024. The company's operating expenses were $22.5 million, with R&D expenses at $20.7 million and G&A expenses at $1.8 million. As of March 31, 2024, Celcuity reported cash, cash equivalents and short-term investments of $177.7 million.
VIKTORIA-1 study remains on track.
The first patient was dosed in Phase 1b/2 trial in metastatic castration resistant prostate cancer.
Began foundational work to prepare for the potential commercial launch of gedatolisib.
Topline data from the PIK3CA wild type patient sub-group will be presented later this year.
Celcuity
Celcuity
Forward Guidance
Celcuity expects cash, cash equivalents, investments and drawdown on our debt facility to fund current operational activities into the first half of 2026.